Movement Alert｜10x Genomics, Inc. After-Hours Rise 5.83%, raised full-year revenue outlook keeps earnings-driven rebound in focus

Market Focus11-12 05:01

On November 12, 10x Genomics, Inc. rose 5.83% in After-Hours Trading, with the stock indicated around $65.67 and turnover of $1.4955 million.

The move followed continued market focus on the company’s stronger-than-expected third-quarter results and higher full-year revenue guidance, which reinforced expectations for operating improvement even as post-earnings valuation debate persisted.

In its latest quarterly report, 10x Genomics, Inc. posted a loss of $0.15 per share, better than expectations for a loss of about $0.25 to $0.27, while revenue reached $150.667 million versus consensus near $148.0 million. The company also lifted full-year revenue guidance to $625 million to $635 million, above the market expectation of about $620.8 million. At the same time, some firms cut their price targets after the results, indicating that the positive earnings surprise has not fully resolved the market’s bull-bear divide.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment